Melanotan II
high riskAlso: MT-2 · PT-14 predecessor · Tanning peptide
Melanotan II is a non-selective melanocortin agonist (MC1R, MC3R, MC4R) developed before PT-141 was derived from it. Causes melanogenesis (tanning) and sexual stimulation via MC4R. Not FDA approved. Higher side effect burden than Melanotan I due to MC3R/MC4R activity.
Reported Benefits
Tanning/melanogenesis
Animal and small human studies confirm pigmentation; no Phase III human tanning trials.
Sexual stimulation
Phase II data for ED; PT-141 (derived from MT-II) subsequently went to FDA approval for HSDD.
Mechanism of Action
Non-selective melanocortin agonist; MC1R drives tanning/melanogenesis; MC4R drives sexual arousal and appetite suppression; MC3R modulates energy homeostasis.
Risk Profile Caveat
Melanotan II is not FDA approved and has a substantially higher side effect burden than its derivatives (Melanotan I for EPP, PT-141/Bremelanotide for HSDD). Nevi (moles) darkening under MT-II requires dermatological monitoring for melanoma risk. The unapproved status and risk profile place it in the high-risk category for unsupervised use.
Regulatory Status
Research OnlySafety Profile
Side Effects
- •Nausea (~50%)
- •Facial flushing
- •Spontaneous erections
- •Appetite suppression
- •Darkening of moles/nevi (monitoring required)
- •Hypertension
Contraindications
- •Melanoma history
- •Cardiovascular disease
- •Pregnancy
Drug Interactions
- •Antihypertensives
- •Vasoactive drugs
Primary Uses
Related Peptides
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe Melanotan II?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →